Our Core Technology
Our vascularized micro-tissues contain a 3D perfused network of living dynamic human vessels. We then functionalize this vascular network by inserting specific tissues of interest, including cancers, such as colon, breast, or brain; and, normal brain with an intact blood brain barrier. The vascularized tissues:
Increased Efficiency in Drug Discovery
Our platforms are designed to increase the efficiency your drug discovery pathway by significantly enhancing the biological authenticity of pre-clinical testing platforms. We can help your team de-risk pre-clinical decisions, so you can move to the next phase of your project with greater confidence. Our experienced team will work with you to custom-design a plan that makes sense for your needs. Core features of our services include,
3D Vascularized Micro-Organ (VMO™)
Our proprietary Vascularized Micro-Organ platform is ideal for studies on vascular permeability, drug delivery, leucocyte adhesion/extravasation and vascular toxicity. The tissue is comprised of extracellular matrix, fibroblasts and a perfused vascular network. The vessels are comprised of endothelial cells and pericytes. The permeability of the vessels approximates those in skin, and flow rate through the vessels can be adjusted as desired.
3D Vascularized Micro-tumor (VMT™)
Our proprietary Vascularized Micro-Tumor platform is based on the 3D-VMO, with the addition of tissue-specific tumor cells. We currently offer the following tumor models:
Additional lines can be established on request. This platform is ideal for screening anti-cancer effects of candidate drugs or transporting cells such as leukocytes to screen immune-oncology reagents.
3D Vascularized Micro-brain (VMB™)
Our proprietary Vascularized Micro-Brain platform is based on the 3D-VMO, and includes vasculature expressing blood-brain barrier (BBB) characteristics. The vessels are wrapped by pericytes and astrocyte foot processes, enriched for BBB markers such as Claudin-5, Occludin, SLC2A1 (Glut-1), ABCB1 (MDR1/P-Glycoprotein) and ABCC4 (MRP4), and show 6 to 10-fold lower permeability than the 3D-VMO vessels. The 3D-VMB platform is ideal for testing drug delivery across the BBB.